Live Breaking News & Updates on Eris lifesciences

Stay informed with the latest breaking news from Eris lifesciences on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Eris lifesciences and stay connected to the pulse of your community

Ahead of Market: 10 things that will decide stock action on Monday

India's benchmark Nifty 50 index hit an all-time high for the fifth time this year on Friday, led by gains in Reliance Industries and IT stocks, and as the government's fiscal prudence in its budget also boosted sentiment.

Germany , India , Ajit-mishra , Sharda-cropchem , Nagaraj-shetti , Grindwell-norton , Reliance-industries , Technical-research , Aditya-birla-corporation , Bank-rs , Tata-steel , Godrej-industries

Samara Capital in fray to invest in PE-backed contract drugmaker

Homegrown private equity firm Samara Capital has emerged as one of the frontrunners to invest in a Mumbai-based pharmaceutical development and manufacturing company, two people ......

Mumbai , Maharashtra , India , Samara , Samarskaya-oblast- , Russia , Sumeet-narang , Gautam-gode , Samara-capital , Oaknet-healthcare , Eris-lifesciences

Q3 result preview: US, India to aid revenue growth for Pharma Inc

The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates.

In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note.

However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.

China , Nirmal , Andhra-pradesh , India , Sun-pharma , Uttam-ghosh-rediff , Lal-pathlabs , Cipla , Pfizer , Axis-securities , Bang-institutional-equities , Nirmal-bang

Dr Reddy's Labs Q3 Preview: Revenue, net profit to record tepid growth on lag in domestic sales

Brokerages believe that DRL's commentary on its US base business and margin trend will remain the key monitorable, especially when the contribution from the generic cancer drug Revlimid is expected to gradually taper off through the coming fiscal.

India , Cipla , Nuvama-institutional-equities , Eris-lifesciences , Kotak-institutional-equities , Dr-reddys-q3 , R-reddys-q3-results , R-reddys-q3-results-updates , R-reddys-q3-earnings , R-reddys-q3-earnings-preview , R-reddys-q3-earnings-updates

Ahead of Market: 10 things that will decide D-Street action on Thursday

Nifty on Wednesday ended 460 points lower to form a red candle on the daily chart with a decisive break below the 20-day moving average of 21,629. Both price and momentum indicators are pointing toward weakness.

China , Cochin , Kerala , India , Netherlands , Chola , Sichuan , Dutch , Etmarkets-whatsapp , Godfrey-philips , Christine-lagarde , Jatin-gedia

UTI Large & mid cap mutual fund has returned 34% in one-year; should you invest?

The fund exhibited erratic outcomes for many years till 2020. Since 2021, the funds return profile has visibly picked up. It must sustain this momentum in order to improve on its earlier patchy track record.

Lifesciences-dec , Indo-count-industries-nov , Value-research , Great-eastern-shipping-company-dec , Clerx-services , Suzlon-energy-nov , Count-industries , Caplin-point-laboratories , Great-eastern-shipping-company , General-insurance-comapny , Suzlon-energy , Eris-lifesciences

UTI Large & Mid Cap Fund has returned 34% in one-year; should you invest?

The fund exhibited erratic outcomes for many years till 2020. Since 2021, the funds return profile has visibly picked up. It must sustain this momentum in order to improve on its earlier patchy track record.

Lifesciences-dec , Value-research , Indo-count-industries-nov , Suzlon-energy-nov , Great-eastern-shipping-company-dec , Clerx-services , Count-industries , Caplin-point-laboratories , Great-eastern-shipping-company , General-insurance-comapny , Suzlon-energy , Eris-lifesciences

Q3 Earnings: PL overweight on banks, underweight on metals; lists Astral, Safari among high conviction picks

The brokerage has increased its weight and remains ‘overweight’ on Banks, Cap Goods and Healthcare, and diversified financials (led by HDFC AMC). It is ‘equal weight’ on IT and ‘underweight’ on Auto, Metals, Cement, Consumer and Oil & Gas.

United-states , India , Hindustan , India-general- , Larsen-toubro , Maruti-suzuki , Ashok-leyland , Siemens , Wipro , Jupiter-health , Reliance-industries , Hindalco-industries

Eris Lifesciences stocks: Buy Eris Lifesciences, target price Rs 1050: Prabhudas Lilladher

Eris Lifesciences Ltd., incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 12633.84 Crore) operating in Pharmaceuticals sector.

Economic-times , Eris-lifesciences-stocks , Markets , Market-news , Sensex , Nifty , Eris-lifesciences , Eris-lifesciences-ltd ,

Nifty Pharma hits all-time high; 10 stocks including Lupin, Cipla, Glenmark Pharma, Divi's Labs touch one-year peaks

In today's trade, Lupin's shares soared nearly 7%, hitting a new all-time high of ₹1,404 apiece after Japanese brokerage firm Nomura raised the target price on the stock to ₹1,593 apiece from the previous ₹1,290, maintaining its 'buy' recommendation.

India , United-states , Japan , Japanese , Prathamesh-masdekar , Sun-pharma , Motilal-oswal , Aurobindo-pharma , Zydus-lifesciences , Research-analyst-at-stoxbox , Glenmark-pharmaceuticals , Glaxosmithkline-pharmaceuticals